Clearmind Medicine Says CMND-100 Meets Primary Goal In Early AUD Study; Stock Up In Pre-Market
Summary
Clearmind Medicine Inc. (CMND) said that CMND-100, the company's proprietary psychedelic treatment has met the primary endpoint in a Phase I/IIa study in Alcoho...
Description
Clearmind Medicine Inc. (CMND) said that CMND-100, the company's proprietary psychedelic treatment has met the primary endpoint in a Phase I/IIa study in Alcoho...
Original reporting
AFBytes is a read-only aggregator. Use the original source for full context and complete reporting.
Open original source